Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asundexian for prevention of recurrent ischemic stroke in non-cardioembolic ischemic stroke or high-risk TIA
CTR20231018Phase 3Completed
- Sponsor
- ---/ 拜耳医药保健有限公司
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of asundexian in ischemic stroke, transient ischaemic attack (TIA), sponsored by ---/ 拜耳医药保健有限公司. Started Apr 2023; status: completed.
02
Drugs
asundexian
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on CTR20231018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231018.